ADIPOTIDE, also referred to in published work as FTPP, is a synthetic chimeric peptide constructed from a vascular-targeting domain fused to a pro-apoptotic effector sequence. AminoOptimization Group supplies it as a lyophilised research powder in 2 mg and 5 mg presentations, tested to 99% purity by HPLC, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.
What is ADIPOTIDE?
ADIPOTIDE is built from two functional domains joined by a short peptide linker. The first is a cyclic, disulfide-constrained targeting sequence originally identified through phage display screening, reported in the literature to bind prohibitin, a protein expressed on the luminal surface of vascular endothelial cells supplying white adipose tissue. The second is D(KLAKLAK)2, a synthetic amphipathic peptide characterized in earlier work for its capacity to disrupt mitochondrial membranes once it reaches the cytosol of a cell.
Neither domain is described as active in isolation the way the fusion construct is. (KLAKLAK)2 alone lacks cell-type selectivity — it disrupts membranes wherever it gains cytosolic access, which is why it is not studied as a standalone agent. Conjugation to the prohibitin-binding domain is described as restricting internalization, and by extension the pro-apoptotic effect, to the cell population reached by the targeting sequence. This ligand-directed design places ADIPOTIDE alongside other targeted pro-apoptotic peptides used in vascular-ablation research, distinct from a conventional receptor agonist or antagonist because the intended mechanism is localized cell death rather than modulation of a signalling pathway.
ADIPOTIDE should not be confused with prohibitin-binding peptides developed for other targeting contexts, nor with unconjugated (KLAKLAK)2, which is a separate research reagent with no targeting domain and a correspondingly different risk and specificity profile in the literature.
Specifications
- Compound: ADIPOTIDE (FTPP)
- CAS number: 859216-15-2
- Molecular formula: C126H210N44O31
- Molecular weight: 2890.3 g/mol
- Purity: 99% by HPLC
- Presentation: Lyophilised powder, sealed vial
- Available sizes: 2 mg, 5 mg
- Physical form: White to off-white powder
- Classification: Research peptide — not for human or veterinary use
Research context
Published research on prohibitin-targeted pro-apoptotic constructs focuses on selective ablation of a specific vascular bed as a tool for studying tissue- and organ-level biology. Work using this class of peptide investigates whether inducing localized apoptosis in the endothelium of white adipose tissue vasculature produces measurable regression of the associated fat depot in rodent and non-human primate models, and what that regression reveals about the relationship between adipose vasculature and depot mass.
Because prohibitin is not expressed exclusively in adipose endothelium, some studies using this construct have also examined signal in renal tissue, since proximal tubule cells have been reported to express the same target protein in certain model systems. This line of investigation is discussed in the literature primarily as a specificity and biodistribution consideration relevant to prohibitin-directed constructs generally. ADIPOTIDE is also examined alongside other ligand-directed pro-apoptotic peptides as a way of comparing targeting domains and vascular-ablation methodology across tissue types.
None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.
Reconstitution
Lyophilised peptide requires reconstitution with a suitable sterile diluent before use in solution. Bacteriostatic water is the diluent most commonly specified for multi-use laboratory preparations; sterile water is typical for single-use work.
Direct the diluent stream against the inner wall of the vial rather than onto the powder itself, and allow the material to dissolve without agitation. Peptides are susceptible to shear stress — do not shake the vial. Swirl gently if needed, and expect full dissolution within a few minutes at room temperature.
Working concentration is a function of how much diluent you add to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.
Storage and stability
Before reconstitution: store the sealed vial in a freezer at -20 °C, protected from light. Lyophilised peptide is comparatively stable in this state. Brief excursions to ambient temperature during shipping are normal and are not expected to compromise a properly lyophilised product.
After reconstitution: refrigerate at 2–8 °C and protect from light. Reconstituted peptide in solution is materially less stable than the dry powder. Avoid repeated freeze-thaw cycles, which are a well-documented cause of aggregation and loss of measurable potency — aliquot instead if repeated sampling is required.
Inspect solutions before use. Cloudiness, visible particulate, or discolouration indicate the material should not be relied upon for quantitative work.
Certificate of Analysis
Every lot is tested by high-performance liquid chromatography, and the purity figure shown above refers to analytical results for the specific lot supplied — not to a generic specification. A Certificate of Analysis is available on request, and we will provide lot-specific documentation before purchase if your protocol requires it.
Purity by HPLC describes the proportion of the target peptide relative to detectable related substances. It is a statement about the material as manufactured and tested. It is expressly not a representation that the material is suitable for any use in humans or animals.
Handling and safety
Handle in accordance with good laboratory practice. Use appropriate personal protective equipment, work in a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation. Anyone with access to this material should understand that it is not for human or veterinary use.
Frequently asked questions
What distinguishes ADIPOTIDE from unconjugated (KLAKLAK)2?
(KLAKLAK)2 alone has no targeting domain and is membrane-disruptive without cell-type selectivity. ADIPOTIDE fuses that sequence to a prohibitin-binding domain, which the literature describes as restricting its pro-apoptotic activity to the cell population reached by the targeting sequence.
Is ADIPOTIDE approved in Canada?
No. This compound has not been evaluated or authorised by Health Canada, the FDA, or any comparable regulatory authority. It carries no DIN or NPN, its safety and efficacy for human use have not been assessed, and it is supplied for laboratory research only.
How much diluent should be used?
That depends on the working concentration your protocol requires. Use the reconstitution calculator to work out the resulting concentration for your vial size.
How long is reconstituted material usable?
Stability in solution is shorter than in lyophilised form and depends on diluent, temperature, and handling. Refrigerate at 2–8 °C, protect from light, avoid freeze-thaw cycling, and validate stability for your own storage conditions if your work depends on it.
Do you provide a Certificate of Analysis?
Yes — lot-specific, available on request, including before purchase.
Research use only
This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.
Reviews
There are no reviews yet.